Liu Anyuan, Liang Tiantian, Wu Weiliang, Weng Jingwen, Wu Hongbing, Zhou Fangyuan, Guo Jeremy
BioDev Drug Product Development Department, WuXi Biologics, 190 Hedan Road, Shanghai 200131, China.
BioDev Drug Product Development Department, WuXi Biologics, 190 Hedan Road, Shanghai 200131, China.
Int J Pharm. 2025 Feb 10;670:125138. doi: 10.1016/j.ijpharm.2024.125138. Epub 2025 Jan 2.
In the realm of therapeutic antibodies, co-formulations comprising two or more monoclonal antibodies (mAbs) have emerged as a promising strategy, offering enhanced treatment efficacy, improved efficiency, and prolonged intellectual property protection. These advantages have sparked significant interest among both patients and pharmaceutical companies. However, the quantification and analysis of individual mAbs within such co-formulations pose a substantial challenge due to their similar physicochemical properties. To address this challenge, we introduce a pH gradient cation exchange chromatography (CEX) method designed to effectively separate three mAbs that share significant similarities in molecular weight, structure, and isoelectric points (pIs) etc. This versatile approach not only facilitates the accurate quantification of each mAb's concentration and their respective ratios within the co-formulation, but also allows for the comprehensive characterization of all charge variants present. In the case of a co-formulation containing three antibodies, the developed CEX method demonstrated superior performance compared to other techniques. The method's robustness was further underscored by its qualification parameters, including acceptable precision (RSD ≤ 3 %), accuracy (95 %-115 % recovery), and linearity (R > 0.99) across a range of 10 to 30 μg load for each mAb. Moreover, the method has been successfully applied in stability studies to quantitatively analyze individual mAb concentrations within co-formulations, marking a significant advancement in the field. Through this work, we contribute a crucial analytical insight into mAb co-formulations, especially those comprising three or more molecules, underscoring its considerable potential to propel the field of biotherapeutic co-formulations forward.
在治疗性抗体领域,包含两种或更多种单克隆抗体(mAb)的联合制剂已成为一种有前景的策略,具有增强的治疗效果、更高的效率以及延长的知识产权保护期。这些优势引发了患者和制药公司的极大兴趣。然而,由于联合制剂中各个单克隆抗体的物理化学性质相似,对其进行定量和分析面临重大挑战。为应对这一挑战,我们引入了一种pH梯度阳离子交换色谱(CEX)方法,该方法旨在有效分离三种在分子量、结构和等电点(pI)等方面具有显著相似性的单克隆抗体。这种通用方法不仅有助于准确量化联合制剂中每种单克隆抗体的浓度及其各自的比例,还能全面表征所有存在的电荷变体。对于含有三种抗体的联合制剂,所开发的CEX方法与其他技术相比表现出卓越性能。该方法的稳健性通过其鉴定参数得到进一步强调,包括在每种单克隆抗体10至30μg上样量范围内可接受的精密度(RSD≤3%)、准确度(回收率95%-115%)和线性度(R>0.99)。此外,该方法已成功应用于稳定性研究,以定量分析联合制剂中各个单克隆抗体的浓度,标志着该领域取得了重大进展。通过这项工作,我们为单克隆抗体联合制剂,尤其是包含三种或更多种分子的联合制剂提供了关键的分析见解,突显了其推动生物治疗联合制剂领域向前发展的巨大潜力。